Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 93, Issue 1, Pages 26-28Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/clpt.2012.207
Keywords
-
Categories
Funding
- National Institutes of Health (NIH) [HL113264, HL075478, HL105339, HL089856, HL083069, HL061795, HL048743, HL107192, HL070819, HL108630]
- NHLBI
- GlaxoSmithKline
- AstraZeneca
- Merck
Ask authors/readers for more resources
Although impressive advances have been made in determining the genetic and molecular causes of disease, treatment for many complex diseases remains inadequate. Despite compelling unmet medical needs and new insights into disease pathobiology, new drug approvals for complex diseases have stagnated. A new paradigm for drug development is needed, and key concepts from network medicine and systems pharmacology may be essential to this effort.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available